NEFL and Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia: Based on compelling evidence from case studies of ALSP and other neurodegenerative disorders, levels of NfL protein in serum and CSF may be predictive of clinical efficacy and should be rigorously tested as a potential biomarker and surrogate clinical endpoint for future clinical trials of therapeutic agents for ALSP.